Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97–78 in rat plasma using the HPLC–ESI-MS/MS method: application to drug interaction study

BACKGROUND: Lumefantrine is the mainstay of anti-malarial combination therapy in most endemic countries presently. However, it cannot be used alone owing to its long onset time of action. CDRI 97–78 is a promising trioxane-derivative anti-malarial candidate that is currently being investigated as a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Malar J
Hauptverfasser: Wahajuddin, Muhammad, Singh, Sheelendra P, Taneja, Isha, Raju, Kanumuri SR, Gayen, Jiaur R, Siddiqui, Hefazat H, Singh, Shio K
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2015
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4429480/
https://ncbi.nlm.nih.gov/pubmed/25895956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12936-015-0684-5
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge